Chugai Pharmaceutical Co., Ltd.
4519
Rank in Stocks
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Share Price
$41.60
Market Cap
$68.46B
Change (1 day)
0.94%
Change (1 year)
-12.56%
Country
JP
Trade Chugai Pharmaceutical Co., Ltd. (4519)
Category
Healthcare
Operating Margin for Chugai Pharmaceutical Co., Ltd. (4519)
Operating Margin as of October 2026 TTM: 47.24%
According to Chugai Pharmaceutical Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 47.24%. At the end of 2024 the company had an Operating Margin of 46.46%.
Operating Margin history for Chugai Pharmaceutical Co., Ltd. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 47.24% | 0.68% |
| 2025 | 46.92% | 0.99% |
| 2024 | 46.46% | 24.22% |
| 2023 | 37.40% | -11.75% |
| 2022 | 42.38% | -2.31% |
| 2021 | 43.38% | 11.23% |
| 2020 | 39.00% | 24.76% |
| 2019 | 31.26% | 40.24% |
| 2018 | 22.29% | 15.61% |
| 2017 | 19.28% | 19.53% |
| 2016 | 16.13% | -9.43% |
| 2015 | 17.81% | 5.63% |
| 2014 | 16.86% | -11.22% |
| 2013 | 18.99% | -2.37% |
| 2012 | 19.45% | 16.40% |
| 2011 | 16.71% | -4.24% |
| 2010 | 17.45% | -9.40% |
| 2009 | 19.26% | 22.13% |
| 2008 | 15.77% | -18.46% |
| 2007 | 19.34% | 8.11% |
| 2006 | 17.89% | -26.07% |
| 2005 | 24.20% | 38.44% |
| 2004 | 17.48% | -4.74% |
| 2003 | 18.35% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 49.72% | -98.95% |
US
|
|
| 25.70% | -99.46% |
US
|
|
| 29.32% | -99.38% |
US
|
|
| 16.65% | -99.65% |
US
|
|
| 26.59% | -99.44% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.